Zhejiang Jingxin Pharmaceutical Co Ltd
002020
Company Profile
Business description
Zhejiang Jingxin Pharmaceutical Co Ltd is an integrated pharmaceuticals enterprise that focuses on manufacturing, R&D, and marketing. It offers finished dosage forms which include tablets, capsules, and injections in the areas of antilipemic, antidiabetic, cholesterolemia, luoroquinolones, cephalosporin, gastrointestinal promotion, anti-inflammatory analgesic, and antibiotics; APIs, and Chinese herbal drugs. The products are sold to overseas markets such as South-east of Asia, South Asia, Latin America and Europe.
Contact
No.800 Xinchang East Road
Yulin subdistrict
Zhejiang Province
Xinchang312500
CHNT: +86 57586298518
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
3,869
Stocks News & Analysis
stocks
After Earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,015.40 | 48.70 | 0.54% |
| CAC 40 | 7,903.68 | 46.32 | 0.59% |
| DAX 40 | 24,255.49 | 38.12 | 0.16% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,119.63 | 16.69 | -0.18% |
| HKSE | 25,176.93 | 347.52 | -1.36% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
| SSE Composite Index | 3,615.72 | 6.01 | 0.17% |